ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting

    Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Francisco Javier Narváez3, Elena Aurrecoechea4, Ignacio Villa-Blanco5, Santos Castañeda6, Catalina Gómez-Arango7, Antonio Mera8, Eva Perez Pampín8, Vicente Aldasoro9, Noelia Álvarez-Rivas10, Nagore Fernandez-Llanio Cornella11, Maria Concepcion Alvarez de Buergo12, Luisa Marena Rojas Vargas13, Francisca Sivera14, Eva Galindez-Agirregoikoa15, Roser Solans16, Susana Romero-Yuste17, Norberto Ortego Centeno18, Marcelino Revenga Martínez19, Rafael Melero20, Eva Salgado-Pérez21, Sabela Fernández22, José Luis Martín-Varillas23, Isabel Martínez-Rodríguez24, Ignacio Banzo24, Vanesa Calvo-Río23, Belén Atienza-Mateo23, Natalia Palmou-Fontana23, Carmen González-Vela25, José Luis Hernández2, Miguel Angel González-Gay23 and Ricardo Blanco23, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 4Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 7Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 8Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 9Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 10Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 11Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 12Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 13Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 14Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 15Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 16Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 17Hospital de Pontevedra. Spain, Pontevedra, Spain, 18Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 19Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 20Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 21Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 22Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 23Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 24Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 25Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…
  • Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting

    Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients

    Monica Calderón Goercke1, Diana Prieto Peña1, Javier Loricera2, Vicente Aldasoro3, Santos Castañeda4, Ignacio Villa-Blanco5, Alicia Humbría4, Clara Moriano Morales6, Susana Romero-Yuste7, Francisco Javier Narváez8, Catalina Gómez-Arango9, Eva Perez Pampín10, Rafael Melero11, Elena Becerra-Fernández12, Marcelino Revenga Martínez13, Noelia Álvarez-Rivas14, Carlos Galisteo15, Francisca Sivera16, Alejandro Olivé-Marqués17, Maria Concepcion Alvarez de Buergo18, Luisa Marena Rojas Vargas19, Carlos Fernandez-Lopez20, Francisco Navarro21, Enrique Raya Álvarez22, Eva Galindez-Agirregoikoa23, Beatriz Arca24, Roser Solans25, Arantxa Conesa26, Cristina Hidalgo-Calleja27, Carlos Vázquez28, Pau Lluch29, Jose Andrés Román Ivorra30, Sara Manrique-Arija31, Paloma Vela32, Eugenio De Miguel33, Carmen Torres-Martín34, Juan Carlos Nieto35, Carmen Ordas-Calvo36, Eva Salgado-Pérez37, Cristina Luna Gómez38, Francisco J. Toyos Sáenz de Miera39, Nagore Fernandez-Llanio Cornella40, Antonio García41, Carmen Larena42, Belén Atienza-Mateo43, José Luis Martín-Varillas43, Natalia Palmou-Fontana43, Vanesa Calvo-Río43, Carmen González-Vela44, Alfonso Corrales43, María Varela-García45, Elena Aurrecoechea46, Raquel Dos Santos47, Angel García-Manzanares12, Norberto Ortego Centeno48, Sabela Fernández49, Francisco Ortiz-Sanjuán50, Montserrat Corteguera34, Miguel Angel González-Gay43, José Luis Hernández2 and Ricardo Blanco43, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 4Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 7Hospital de Pontevedra. Spain, Pontevedra, Spain, 8Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 9Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 10Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 11Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 12Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, 13Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 14Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 15Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, 16Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 17Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 18Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 19Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 20Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, 21Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 22Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 23Rheumatology, University Hospital of Basurto, Bilbao, Spain, 24Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 25Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 26Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 27Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, 28Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, 29Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, 30Hospital La Fe. Valencia. Spain, Valencia, Spain, 31Medicine, University of Málaga, MÁLAGA, Spain, 32Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 33Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 34Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, 35Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 36Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 37Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 38Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 39Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 40Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 41Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, 42Hospital General Universitario Gregorio Marañón, Madrid, Spain, 43Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 44Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 45Complejo Hospitalario de Navarra, Navarra, Spain, 46Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 47Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, 48Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 49Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 50Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain

    Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…
  • Abstract Number: 2755 • 2018 ACR/ARHP Annual Meeting

    Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Clara Moriano Morales3, Elvira Diez Alvarez4, Francisco Javier Narváez5, Antonio Mera6, Eva Perez Pampín6, Vicente Aldasoro7, María Varela-García8, Noelia Álvarez-Rivas9, Ceferino Barbazan10, Carmen Ordas-Calvo11, Francisca Sivera12, Cristina Luna Gómez13, Francisco J. Toyos Sáenz de Miera14, Arantxa Conesa15, Francisco Navarro16, Belén Atienza-Mateo17, José Luis Martín-Varillas17, Eva Galindez-Agirregoikoa18, Vanesa Calvo-Río17, Carmen González-Vela19, Natalia Palmou-Fontana2, José Luis Hernández2, Miguel Angel González-Gay2 and Ricardo Blanco17, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 4Complejo Asistencial Universitario de León, León, Spain, 5Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, 6Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 7Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 8Complejo Hospitalario de Navarra, Navarra, Spain, 9Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 10Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 11Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 12Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 13Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 14Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 15Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 16Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 17Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 18Rheumatology, University Hospital of Basurto, Bilbao, Spain, 19Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

     Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a special predilection for extracranial branches of the external carotid artery. Among its most…
  • Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting

    A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial

    Monica Calderón Goercke1, Javier Loricera2, Diana Prieto Peña1, Vicente Aldasoro3, Santos Castañeda4, Ignacio Villa-Blanco5, Alicia Humbría6, Clara Moriano Morales7, Susana Romero-Yuste8, Francisco Javier Narváez9, Catalina Gómez-Arango10, Eva Perez Pampín11, Rafael Melero12, Elena Becerra-Fernández13, Marcelino Revenga Martínez14, Noelia Álvarez-Rivas15, Carlos Galisteo16, Francisca Sivera17, Alejandro Olivé-Marqués18, Maria Concepcion Alvarez de Buergo19, Luisa Marena Rojas Vargas20, Carlos Fernandez-Lopez21, Francisco Navarro22, Enrique Raya Álvarez23, Eva Galindez-Agirregoikoa24, Beatriz Arca25, Roser Solans26, Arantxa Conesa27, Cristina Hidalgo-Calleja28, Carlos Vázquez29, Jose Andrés Román Ivorra30, Pau Lluch31, Sara Manrique-Arija32, Paloma Vela33, Eugenio De Miguel34, Carmen Torres-Martín35, Juan Carlos Nieto36, Carmen Ordas-Calvo37, Eva Salgado-Pérez38, Cristina Luna Gómez39, Francisco J. Toyos Sáenz de Miera40, Nagore Fernandez-Llanio Cornella41, Antonio García42, Carmen Larena43, Belén Atienza-Mateo44, José Luis Martín-Varillas44, Natalia Palmou-Fontana2, Vanesa Calvo-Río44, Carmen González-Vela45, Alfonso Corrales44, María Varela-García46, Elena Aurrecoechea47, Raquel Dos Santos48, Angel García-Manzanares13, Norberto Ortego Centeno49, Sabela Fernández50, Francisco Ortiz-Sanjuán51, Montserrat Corteguera35, Miguel Angel González-Gay2, José Luis Hernández2 and Ricardo Blanco44, 1Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, 4Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 6Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 7Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, 8Hospital Pontevedra. Pontevedra. Spain., Pontevedra, Spain, 9Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, 10Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, 11Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 12Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, 13Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, 14Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, 16Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, 17Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, 18Hospital Trías i Pujol, Badalona, Barcelona, Spain, 19Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, 20Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 21Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, 22Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, 23Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 24Rheumatology, University Hospital of Basurto, Bilbao, Spain, 25Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 26Systemic Autoimmune Diseases Unit, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, 27Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, 28Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, 29Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, 30Hospital La Fe. Valencia. Spain, Valencia, Spain, 31Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, 32UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain., Málaga, Spain, 33Reumatología, Hospital General Universitario Alicante, Alicante, Spain, 34Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 35Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, 36Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 37Hospital Cabueñes, Gijón. Spain, Gijón, Spain, 38Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, 39Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, 40Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, 41Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, 42Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, 43Hospital General Universitario Gregorio Marañón, Madrid, Spain, 44Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 45Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 46Complejo Hospitalario de Navarra, Navarra, Spain, 47Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 48Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, 49Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 50Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, 51Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain

    Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
  • Abstract Number: 2757 • 2018 ACR/ARHP Annual Meeting

    A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing

    Navita L. Mallalieu1, John H. Stone2, Peter M. Villiger3, Micki Klearman4, Laura Brockwell5, Sophie Dimonaco5 and Jean Eric Charoin6, 1Roche Innovation Center, New York, NY, 2Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3University of Bern, Bern, Switzerland, 4Genentech, Inc., South San Francisco, CA, 5Roche Products Ltd, Welwyn Garden City, United Kingdom, 6Roche Innovation Center (Basel), Basel, Switzerland

    Background/Purpose: Tocilizumab (TCZ), an anti–interleukin-6 receptor (IL-6R) monoclonal antibody, was recently approved for the treatment of patients with giant cell arteritis (GCA) based on results…
  • Abstract Number: 2758 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study

    Carlotta Nannini1, Laura Niccoli2, Emanuele Antonio Maria Cassarà2, Olga Kaloudi2, Stelvio Sestini3 and Fabrizio Cantini2, 1Prato Hospital, Prato, Italy, 2Rheumatology, Prato Hospital, Prato, Italy, 3Radiology, Prato Hospital, Prato, Italy

    Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was…
  • Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting

    Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis

    Shubhasree Banerjee1, Kaitlin Quinn2, Katherine B. Gribbons3, Joel S. Rosenblum4, Ali Civelek5, Elaine Novakovich6, Armin Bagheri1, Peter A. Merkel7, Mark A. Ahlman8 and Peter C. Grayson9, 1Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, 2Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, 4NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 5National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 7University of Pennsylvania, Philadelphia, PA, 8Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 9National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

    Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…
  • Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

    Sebastian H. Unizony1, Jinglan Pei2, Páris N. Sidiropoulos2, Jennie H. Best2, Christine Birchwood2 and John H. Stone3, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, CA, 3Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
  • Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting

    High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

    Sarah H. Chung1, Meredith B. Morcos1 and Bernard Ng1,2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…
  • Abstract Number: 2762 • 2018 ACR/ARHP Annual Meeting

    A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort

    Sarah H. Chung1, Meredith B. Morcos1 and Bernard Ng1,2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Rheumatology, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: TAB is currently considered the gold standard for the diagnosis of GCA. However, it is suspected that the sensitivity of TAB is limited by…
  • Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting

    Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis

    Matthew J. Koster1, Melissa Snyder2, Michel Villatoro-Villar1, Cynthia S. Crowson3, Tanaz A. Kermani4 and Kenneth J. Warrington5, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
  • Abstract Number: 2764 • 2018 ACR/ARHP Annual Meeting

    Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data

    Valérie Devauchelle-Pensec1, Eric Hachulla2, Marc Paccalin3, Sophie Gandon4, Isabelle Idier5, Maeva Nolin6, Manon Belhassen6 and Alfred Mahr7, 1Department of Rheumatology and Unit of Immunology, University Medical School, Brest, France, 2Department of Internal Medicine, University Lille Nord-de-France, Lille, France, 3Department of Geriatric Medicine, University Hospital, Poitiers, France, 4Clinical Operation, Roche SAS, Boulogne-Billancourt, France, 5Medical department, Chugai Pharma France, Paris La Defense, France, 6PELyon, Pharmacoepidemiologie, Lyon, France, 7Hospital Saint-Louis, University Paris Diderot, Paris, France

    Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated, primary systemic vasculitis that affects large and medium-sized arteries. GCA may cause vision loss in up to…
  • Abstract Number: 2765 • 2018 ACR/ARHP Annual Meeting

    Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort

    Rok Jese, Ziga Rotar, Matija Tomsic and Alojzija Hočevar, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: The inflammation of thyroid arteries (ThA) is not commonly considered and investigated in giant cell arteritis (GCA). We aimed to estimate the frequency of…
  • Abstract Number: 2766 • 2018 ACR/ARHP Annual Meeting

    Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study

    Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1St. Joseph's Hospital, Chicago, IL, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: To determine whether there is a seasonal peak onset of giant cell arteritis (GCA). We examined the seasonal variability of GCA in a geographically-defined…
  • Abstract Number: 2767 • 2018 ACR/ARHP Annual Meeting

    Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study

    Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1St. Joseph's Hospital, Chicago, IL, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: The presence of varicella zoster virus (VZV) signal in the temporal arteries of patients with giant cell arteritis has suggested a possible role of…
  • « Previous Page
  • 1
  • …
  • 1186
  • 1187
  • 1188
  • 1189
  • 1190
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology